The kidney disease wasting: Inflammation, oxidative stress, and diet-gene interaction

Hemodialysis International

Volumn 10, Issue 4, 2006, Pages 315-325

  Kalantar Zadeh, Kamyar ^a   Balakrishnan, Vaidyanathapuram S ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Genetic polymorphism; Inflammation; Kidney disease wasting; Malnutrition; Oxidative stress; Reverse epidemiology

Indexed keywords

ALPHA TOCOPHEROL; ATORVASTATIN; C REACTIVE PROTEIN; CARNITINE; FISH OIL; FOLIC ACID; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; REACTIVE OXYGEN METABOLITE;

ANOREXIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DEATH; DIABETES MELLITUS; DIALYSIS MEMBRANE; DIET; DIET SUPPLEMENTATION; DISEASE EXACERBATION; ENDOTHELIAL DYSFUNCTION; ENZYME BLOOD LEVEL; EPIDEMIC; GENETIC POLYMORPHISM; HEMODIALYSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPOALBUMINEMIA; INFLAMMATION; MAINTENANCE THERAPY; MORTALITY; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PREVALENCE; QUALITY OF LIFE; REVIEW; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; WASTING SYNDROME; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; CYTOKINES; DIET; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS; MODELS, BIOLOGICAL; OXIDATIVE STRESS; POLYMORPHISM, GENETIC; PROGNOSIS; RENAL DIALYSIS; RISK FACTORS;

EID: 33748091826     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2006.00124.x     Document Type: Review

References (115)

1. United States Renal Data System. Excerpts from the USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Am J Kid Dis. 2006; 47 (Suppl 1): 1-286.
2. United States Renal Data System. US Department of Public Health and Human Services, Public Health Service, National Institutes of Health, Bethesda, 2002.
3. National Kidney Foundation I, Kidney-Dialysis Outcome Quality Initiative: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Am J Kidney Dis. 2002; 39.
4. Kalantar-Zadeh K, Abbott KC, Kronenberg F, Anker SD, Horwich TB, Fonarow GC. Epidemiology of dialysis patients and heart failure patients; special review article for the 25th anniversary of the Seminars in Nephrology. Semin Nephrol. 2006; 26: 118-133.
5. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353: 238-248.
6. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol. 2004; 15: 420-426.
7. Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol. 2004; 15: 442-453.
8. Suliman ME, Barany P, Kalantar-Zadeh K, Lindholm B, Stenvinkel P. Homocysteine in uraemia - a puzzling and conflicting story. Nephrol Dial Transplant. 2005; 20: 16-21.
9. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002; 347: 2010-2019.
10. Paniagua R, Amato D, Vonesh E, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol. 2002; 13: 1307-1320.
11. Kalantar-Zadeh K, Kopple JD. Obesity paradox in patients on maintenance dialysis. Contributions Nephrol. 2006; 151: 57-69.
12. Kalantar-Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB. Survival advantages of obesity in dialysis patients. Am J Clin Nutr. 2005; 81: 543-554.
13. Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, et al. Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am J Kidney Dis. 2005; 46: 489-500.
14. Kalantar-Zadeh K, Kuwae N, Wu DY, et al. Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutr. 2006; 83: 202-210.
15. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003; 63: 793-808.
16. Kopple JD. The phenomenon of altered risk factor patterns or reverse epidemiology in persons with advanced chronic kidney failure. Am J Clin Nutr. 2005; 81: 1257-1266.
17. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, Wu DY. Reverse epidemiology: A spurious hypothesis or a hardcore reality? Blood Purif. 2005; 23: 57-63.
18. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition-inflammation complex syndrome in dialysis patients: Causes and consequences. Am J Kidney Dis. 2003; 42: 864-881.
19. Kalantar-Zadeh K, Kopple JD. Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. Am J Kidney Dis. 2001; 38: 1343-1350.
20. Bergstrom J. Inflammation, malnutrition, cardiovascular disease and mortality in end-stage renal disease. Pol Arch Med Wewn. 2000; 104: 641-643.
21. Qureshi AR, Alvestrand A, Divino-Filho JC, et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol. 2002; 13 (Suppl 1): S28-S36.
22. Stenvinkel P. Malnutrition and chronic inflammation as risk factors for cardiovascular disease in chronic renal failure. Blood Purif. 2001; 19: 143-151.
23. Stenvinkel P, Chung SH, Heimburger O, Lindholm B. Malnutrition, inflammation, and atherosclerosis in peritoneal dialysis patients. Perit Dial Int. 2001; 21 (Suppl 3): S157-S162.
24. Ifudu O, Uribarri J, Rajwani I, et al. Low hematocrit may connote a malnutrition-inflammation syndrome in hemodialysis patients. Dial Transplant. 2002; 845: 845-878.
25. Stenvinkel P, Heimburger O, Lindholm B, Kaysen GA, Bergstrom J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant. 2000; 15: 953-960.
26. Nomenclature consensus conference: Kidney disease wasting. In: Fouque D, Kalantar-Zadeh K. eds. Organizing the XIII International Congress on Metabolism and Nutrition in Renal Disease. Mexico: Merida; 2006.
27. Kalantar-Zadeh K, Block G, McAllister CJ, Humphreys MH, Kopple JD. Appetite and inflammation, nutrition, anemia and clinical outcome in hemodialysis patients. Am J Clin Nutr. 2004; 80: 299-307.
28. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, et al. Revisiting mortality predictability of serum albumin in the dialysis population: Time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant. 2005; 20: 1880-1889.
29. Shinaberger CS, Kilpatrick RD, Regidor DL, et al. Longitudinal associations between dietary protein intake and survival in hemodialysis patients. Am J Kid Dis. 2006; 48: 37-49.
30. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347: 1557-1565.
31. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005; 352: 20-28.
32. Kalantar-Zadeh K. Recent advances in understanding the malnutrition-inflammation-cachexia syndrome in chronic kidney disease patients: What is next? Semin Dial. 2005; 18: 365-369.
33. Kalantar-Zadeh K, Stenvinkel P, Pillon L, Kopple JD. Inflammation and nutrition in renal insufficiency. Adv Ren Replace Ther. 2003; 10: 155-169.
34. Stenvinkel P, Barany P, Heimburger O, Pecoits-Filho R, Lindholm B. Mortality, malnutrition, and atherosclerosis in ESRD: What is the role of interleukin-6? Kidney Int. 2002; (Suppl 2): 103-108.
35. Beddhu S, Kaysen GA, Yan G, et al. Association of serum albumin and atherosclerosis in chronic hemodialysis patients. Am J Kidney Dis. 2002; 40: 721-727.
36. Mezzano D, Pais EO, Aranda E, et al. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int. 2001; 60: 1844-1850.
37. Kalantar-Zadeh K, Stenvinkel P, Bross R, et al. Kidney insufficiency and nutrient-based modulation of inflammation. Curr Opin Clin Nutr Metab Care. 2005; 8: 388-396.
38. Kalantar-Zadeh K, Kamranpour N, Kopple JD. Association between novel HDL inflammatory/anti-inflammatory properties with body mass index in hemodialysis patients. J Am Soc Nephrol. 2004; 15 (Suppl): 172A. [abstract].
39. Kalantar-Zadeh K, Kopple JD, Kamranpour N, Navab M. Novel HDL inflammatory/anti-inflammatory properties correlate with total body fat in hemodialysis patients. J Am Soc Nephrol. 2005; 16: 273A [abstract].
40. Sies H. Oxidative stress: Oxidants and antioxidants. Exp Physiol. 1997; 82: 291-295.
41. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: An emerging threat to patient outcome. Nephrol Dial Transplant. 2003; 18: 1272-1280.
42. Handelman GJ. Current studies on oxidant stress in dialysis. Blood Purif. 2003; 21: 46-50.
43. Handelman GJ. Evaluation of oxidant stress in dialysis patients. Blood Purif. 2000; 18: 343-349.
44. Danielski M, Ikizler TA, McMonagle E, et al. Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy. Am J Kidney Dis. 2003; 42: 286-294.
45. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002; 62: 1524-1538.
46. Descamps-Latscha B, Goldfarb B, Nguyen AT, et al. Establishing the relationship between complement activation and stimulation of phagocyte oxidative metabolism in hemodialyzed patients: A randomized prospective study. Nephron. 1991; 59: 279-285.
47. Witko-Sarsat V, Gausson V, Nguyen AT, et al. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: A potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int. 2003; 64: 82-91.
48. Kalantar-Zadeh K, Kopple JD, Deepak S, Block D, Block G. Food intake characteristics of hemodialysis patients as obtained by food frequency questionnaire. J Ren Nutr. 2002; 12: 17-31.
49. Kalantar-Zadeh K, Kopple J. Nutritional management of hemodialysis patients. In: Massry S ed. Nutritional Management of Renal Disease. 2nd ed. Philadelphia: Lippincott, Williams & Wilkins; 2003, 134-152.
50. Descamps-Latscha B, Drueke T, Witko-Sarsat V. Dialysis-induced oxidative stress: Biological aspects, clinical consequences, and therapy. Semin Dial. 2001; 14: 193-199.
51. Canaud B, Cristol J, Morena M, Leray-Moragues H, Bosc J, Vaussenat F. Imbalance of oxidants and antioxidants in haemodialysis patients. Blood Purif. 1999; 17: 99-106.
52. Nguyen AT, Lethias C, Zingraff J, Herbelin A, Naret C, Descamps-Latscha B. Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within microamounts of whole blood. Kidney Int. 1985; 28: 158-167.
53. Kalantar-Zadeh K, Kilpatrick RD, Kopple JD, Stringer WW. A matched comparison of serum lipids between hemodialysis patients and nondialysis morbid controls. Hemodial Int. 2005; 9: 314-324.
54. Navab M, Ananthramaiah GM, Reddy ST, et al. Thematic review series: The pathogenesis of atherosclerosis: The oxidation hypothesis of atherogenesis: The role of oxidized phospholipids and HDL. J Lipid Res. 2004; 45: 993-1007.
55. Huang YH, Ronnelid J, Frostegard J. Oxidized LDL induces enhanced antibody formation and MCH class II-dependent INF-gamma production in lymphocytes from healthy individuals. Arterioscler Thromb Vasc Biol. 1995; 15: 1577-1583.
56. Jovinge S, Ares MP, Kallin B, Nilsson J. Human monocytes/macrophages release TNF alpha in response to oxidized LDL. Arterioscler Thromb Vasc Biol. 1996; 1996: 1573-1579.
57. Navab M, Berliner JA, Watson AD, et al. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol. 1996; 16: 831-842.
58. Navab M, Hama SY, Ready ST, et al. Oxidized lipids as mediators of coronary heart disease. Curr Opin Lipidol. 2002; 13: 363-372.
59. Ok E, Basnakian AG, Apostolov EO, Barri YM, Shah SV. Carbamylated low-density lipoprotein induces death of endothelial cells: A link to atherosclerosis in patients with kidney disease. Kidney Int. 2005; 68: 173-178.
60. Apostolov EO, Shah SV, Ok E, Basnakian AG. Quantification of carbamylated LDL in human sera by a new sandwich ELISA. Clin Chem. 2005; 51: 719-728.
61. Shishehbor MH, Hazen SL. Antioxidant studies need a change of direction. Clev Clin J Med. 2004; 71: 285-288.
62. Shishehbor MH, Hazen SL. Inflammatory and oxidative markers in atherosclerosis: Relationship to outcome. Curr Atheroscler Rep. 2004; 6: 243-250.
63. Kalantar-Zadeh K, Brennan ML, Hazen SL. Serum myeloperoxidase levels predict mortality in maintenance hemodialysis patients. Am J Kid Dis. 2006; 48: 59-68.
64. Navab M, Berliner JA, Subbanagounder G, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2001; 21: 481-488.
65. Ansell BJ, Navab M, Hama S, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003; 108: 2751-2756.
66. Pawlak K, Borawski J, Naumnik B, Mysliwiec M. Relationship between oxidative stress and extrinsic coagulation pathway in haemodialyzed patients. Thromb Res. 2003; 109: 247-251.
67. Biasioli S, Schiavon R, Petrosino L, et al. Paraoxonase activity and paraoxonase 1 gene polymorphism in patients with uremia. ASAIO J. 2003; 49: 295-299.
68. Schiavon R, De Fanti E, Giavarina D, Biasioli S, Cavalcanti G, Guidi G. Serum paraoxonase activity is decreased in uremic patients. Clin Chim Acta. 1996; 247: 71-80.
69. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol. 2004; 43: 1439-1444.
70. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol. 2004; 43: 1434-1444.
71. Wilson DO, Rogers RM, Wright EC, Anthonisen NR. Body weight in chronic obstructive pulmonary disease. The National Institutes of Health Intermittant Positive-Pressure Breathing Trial. Am Rev Respir Dis. 1989; 139: 1435-1438.
72. Horwich TB, Fonarow GC. The impact of obesity on survival in patients with heart failure. Heart Fail Monit. 2002; 3: 8-14.
73. Hasper D, Hummel M, Kleber FX, Reindl I, Volk HD. Systemic inflammation in patients with heart failure. Eur Heart J. 1998; 19: 761-765.
74. Conraads VM, Bosmans JM, Vrints CJ. Chronic heart failure: An example of a systemic chronic inflammatory disease resulting in cachexia. Int J Cardiol. 2002; 85: 33-49.
75. Rauchhaus M, Koloczek V, Volk H, et al. Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol. 2000; 76: 125-133.
76. Hosoya N, Sakai K. Backdiffusion rather than backfiltration enhances endotoxin transport through highly permeable dialysis membranes. ASAIO Trans. 1990; 36: M311-M313.
77. Laude-Sharp M, Caroff M, Simard L, Pusineri C, Kazatchkine M, Haeffner-Cavaillon N. Induction of IL-1 during hemodialysis: Transmembrane passage of intact endotoxin (LPS). Kidney Int. 1990; 38: 1089-1094.
78. Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: A prospective cohort study. Lancet. 1999; 353: 1838-1842.
79. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet. 2000; 356: 930-933.
80. Suffredini AF, Fantuzzi G, Badolato R, Oppenheim JJ, O'Grady NP. New insights into the biology of the acute phase response. J Clin Immunol. 1999; 19: 203-214.
81. Tielemans C, Husson C, Schurmans T, et al. Effects of ultrapure and non-sterile dialysate on the inflammatory response during in vitro hemodialysis. Kidney Int. 1996; 49: 236-243.
82. Kalantar-Zadeh K, Fouque D, Kopple JD. Outcome research, nutrition, and reverse epidemiology in maintenance dialysis patients. J Ren Nutr. 2004; 14: 64-71.
83. Owen WF Jr., Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med. 1993; 329: 1001-1006.
84. Combe C, Chauveau P, Laville M, et al. Influence of nutritional factors and hemodialysis adequacy on the survival of 1,610 French patients. Am J Kidney Dis. 2001; 37: S81-S88.
85. Ling PR, Smith RJ, Kie S, Boyce P, Bistrian BR. Effects of protein malnutrition on IL-6-mediated signaling in the liver and the systemic acute-phase response in rats. Am J Physiol Regul Integr Comp Physiol. 2004; 287: R801-R808.
86. Jenkins DJ, Kendall CW, Marchie A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA. 2003; 290: 502-510.
87. Esposito K, Marfella R, Ciotola M, et al. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: A randomized trial. JAMA. 2004; 292: 1440-1446.
88. McCarthy DO. Rethinking nutritional support for persons with cancer cachexia. Biol Res Nurs. 2003; 5: 3-17.
89. Watson J, Byars ML, McGill P, Kelman AW. Cytokine and prostaglandin production by monocytes of volunteers and rheumatoid arthritis patients treated with dietary supplements of blackcurrant seed oil. Br J Rheumatol. 1993; 32: 1055-1058.
90. Curtis CL, Harwood JL, Dent CM, Caterson B. Biological basis for the benefit of nutraceutical supplementation in arthritis. Drug Discov Today. 2004; 9: 165-172.
91. Vergili-Nelsen JM. Benefits of fish oil supplementation for hemodialysis patients. J Am Diet Assoc. 2003; 103: 1174-1177.
92. Mayer K, Meyer S, Reinholz-Muhly M, et al. Short-time infusion of fish oil-based lipid emulsions, approved for parenteral nutrition, reduces monocyte proinflammatory cytokine generation and adhesive interaction with endothelium in humans. J Immunol. 2003; 171: 4837-4843.
93. Pakala R, Sheng WL, Benedict CR. Vascular smooth muscle cells preloaded with eicosapentaenoic acid and docosahexaenoic acid fail to respond to serotonin stimulation. Atherosclerosis. 2000; 153: 47-57.
94. McCarty MF. A central role for protein kinase C overactivity in diabetic glomerulosclerosis: Implications for prevention with antioxidants, fish oil, and ACE inhibitors. Med Hypotheses. 1998; 50: 155-165.
95. Kutner NG, Clow PW, Zhang R, Aviles X. Association of fish intake and survival in a cohort of incident dialysis patients. Am J Kidney Dis. 2002; 39: 1018-1024.
96. Hirai A, Terano T, Tamura Y, Yoshida S. Eicosapentaenoic acid and adult diseases in Japan: Epidemiological and clinical aspects. J Intern Med. 1989; 225 (Suppl): 69-75.
97. Gadek JE, DeMichele SJ, Karlstad MD, et al. Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Enteral Nutrition in ARDS Study Group. Crit Care Med. 1999; 27: 1409-1420.
98. Mancuso P, Whelan J, DeMichele SJ, et al. Effects of eicosapentaenoic and gamma-linolenic acid on lung permeability and alveolar macrophage eicosanoid synthesis in endotoxic rats. Crit Care Med. 1997; 25: 523-532.
99. Kalantar-Zadeh K, Braglia A, Chow J, et al. An anti-inflammatory and antioxidant nutritional supplement for hypoalbuminemic hemodialysis patients: A pilot/feasibility study. J Ren Nutr. 2005; 15: 318-331.
100. Rammohan M, Kalantar-Zadeh K, Liang A, Ghossein C. Megestrol acetate in a moderate dose for the treatment of malnutrition-inflammation complex in maintenance dialysis patients. J Ren Nutr. 2005; 15: 345-355.
101. Colman S, Bross R, Benner D, et al. The nutritional and inflammatory evaluation in dialysis patients (NIED) study: Overview of the NIED study and the role of dietitians. J Ren Nutr. 2005; 15: 231-243.
102. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004; 164: 659-663.
103. Chen K, Li F, Li J, et al. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med. 2006; 12: 425-432.
104. Hsu C-Y, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006; 144: 21-28.
105. Chertow GM, Hsu CY, Johansen KL. The enlarging body of evidence: Obesity and chronic kidney disease. J Am Soc Nephrol. 2006; 17: 1501-1502.
106. Pankow JS, Folsom AR, Cushman M, et al. Familial and genetic determinants of systemic markers of inflammation: The NHLBI family heart study. Atherosclerosis. 2001; 154: 681-689.
107. Tsirpanlis G, Bagos P, Ioannou D, et al. The variability and accurate assessment of microinflammation in haemodialysis patients. Nephrol Dial Transplant. 2004; 19: 150-157.
108. Yao Q, Lindholm B, Stenvinkel P. Inflammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients. Hemodial Int. 2004; 8: 118-129.
109. Szalai AJ, McCrory MA, Cooper GS, Wu J, Kimberly RP. Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun. 2002; 3: 14-19.
110. Daly MJ, Rioux JD, Schaffner SF, Hudson TJ, Lander ES. High-resolution haplotype structure in the human genome. Nat Genet. 2001; 29: 229-232.
111. Patil N, Berno AJ, Hinds DA, et al. Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science. 2001; 294: 1719-1723.
112. Kruglyak L, Nickerson DA. Variation is the spice of life. Nat Genet. 2001; 27: 234-236.
113. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet. 2004; 74: 106-120.
114. Johnson GC, Esposito L, Barratt BJ, et al. Haplotype tagging for the identification of common disease genes. Nat Genet. 2001; 29: 233-237.
115. Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ. The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J. 2001; 22: 2243-2252.